Why the study?
Does MAPIE improve outcomes compared to MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma?
Does MAPIE improve outcomes compared to MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma?
Avoid MAPIE in poor responders to preoperative MAP; reinforces MAP as standard of care while underscoring need for novel strategies.
UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.
No takes yet. Share an insight, caveat, or question.
Marina et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: